Pharma: Page

  • A doctor and a businessperson shaking hands.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    As pharma M&A ramps up, U.S. execs are bullish on more deals

    What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

    By Michael Gibney • Aug. 11, 2022
  • ARLINGTON, VA - JUNE 05: Recently laid off worker Lyn Talent receives a free Botox injection during an event called the "The Botox Bailout."
    Image attribution tooltip
    Win McNamee/Staff via Getty Images
    Image attribution tooltip

    Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics

    Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.

    By Michael Gibney • Aug. 11, 2022
  • tech clinical trial Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Tech for Clinical Trials

    Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.

    By PharmaVoice staff
  • cell therapy infusion
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    4 ways to nail the launch of your cell therapy

    A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

    By • Aug. 10, 2022
  • Seen from behind, a clinician is using a cell phone and checking a patient's electronic health record on a laptop.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    How real world evidence is impacting rare disease drug development

    ICON’s Will Maier shares how a more patient-focused approach to trials is leading to alternatives for randomization.

    By Kim Ribbink • Aug. 9, 2022
  • A baby harp seal pup lays on ice in the White Sea.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Turning harp seal contraceptives into a ‘new genre’ of cancer treatments

    With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.

    By Alexandra Pecci • Aug. 9, 2022
  • CEO pay
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Are Big Pharma CEOs earning their pay?

    While compensation packages at the top may not always reflect value, it’s not necessarily an industrywide problem.

    By Kelly Bilodeau • Aug. 8, 2022
  • monkeypox vax
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    The ‘alarming’ spread of Monkeypox — by the numbers

    With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’

    By • Aug. 8, 2022
  • Pills, blister packs, medical bottles, laptop
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Generic subscription services like Mark Cuban’s promise cheaper drugs — but will it work?

    Companies like Cost Plus Drugs and DiRx can bring generics directly to consumers at a fraction of the price, but whether it’s enough to fix the inflated U.S. healthcare system is yet to be seen.

    By Michael Gibney • Aug. 4, 2022
  • A hand picks a blue figurine out of rows of similar wooden figurines.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Making Moves

    Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

    How these latest executive personnel changes are impacting the industry. 

    By Karissa Waddick • Aug. 3, 2022
  • A physician in a white scrubs assists a blue-shirted patient.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients

    EverythingALS aims to speed drug development through improved diagnostics.

    By Kelly Bilodeau • Aug. 2, 2022
  • A collage of pnk, blue and orange bacteria-like blobs float around against a dark blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Taking probiotics where they’ve never gone before

    How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.

    By Karissa Waddick • Aug. 2, 2022
  • Catherine Owen
    Image attribution tooltip

    Permission granted by Catherine Owen.

    Image attribution tooltip
    Q&A

    A glimpse inside Bristol Myers Squibb’s integration with Celgene

    Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.

    By • Aug. 1, 2022
  • Artifical intelligence
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

    WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

    By Kim Ribbink • Aug. 1, 2022
  • A nurse in green scrubs puts a smart watch on a patient in a grey, blue and orange striped shirt.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    Personalized data could bring PhysIQ to the forefront of clinical trial evolution

    The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.

    By Karissa Waddick • July 28, 2022
  • A person points a pen at a computer with a green line graph. A blurred computer in the background shows other graphs.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    What’s next for Biogen? Here’s what executives are saying

    A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?

    By Michael Gibney • July 27, 2022
  • A view of the Capitol Dome from below with an American flag waving in the wind on the left side and blue skies in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Democrats think they've found a balance between drug innovation and pricing negotiation

    A look at Congress’ push to pass drug pricing reform and why the latest attempt could actually succeed.

    By Karissa Waddick • July 26, 2022
  • A man walks out of the Pfizer world headquarters building.
    Image attribution tooltip
    Chris Hondros / Staff via Getty Images
    Image attribution tooltip
    Q&A

    Behind Pfizer's new quest to target a 'transformation' in pharma

    A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

    By Kelly Bilodeau • July 25, 2022
  • Neuron
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets

    The latest trial failures in Alzheimer's have shown cracks in the foundation of ingrained theories like amyloid plaque clearance. What will it take to move forward?

    By Michael Gibney • July 25, 2022
  • J&J CEO Joaquin Duato
    Image attribution tooltip
    Mike Coppola via Getty Images
    Image attribution tooltip

    With big changes ahead for J&J and Novartis, here's what the companies' execs are talking about

    Both J&J and Novartis are making — or considering — big shifts in their fundamental company makeup.

    By Michael Gibney • July 21, 2022
  • A person wearing a purple latex glove holds a petri dish with pink and red spots vertically with their thumb and index finger.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    By the numbers: The rising danger of superbugs

    A look at how the COVID-19 pandemic exacerbated one of the world’s greatest public health concerns.

    By Karissa Waddick • July 20, 2022
  • John LaMattina
    Image attribution tooltip

    Permission granted by John LaMattina

    Image attribution tooltip

    Pfizer's former R&D head takes on drug pricing misconceptions in new book

    John LaMattina has something to say about the industry — and he hopes patients are listening.

    By • July 19, 2022
  • R&D costs
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biotech R&D spending has skyrocketed, and so have opportunities for savings

    With R&D costs on the rise, biotechs are embracing new strategies and technologies to make spending more efficient.

    By Michael Gibney • July 19, 2022
  • A person holds a magnet pointed at multi-colored wooden figures of people sitting on dark wood-grain table.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Making Moves

    Making moves: Agios, BeiGene, Biocom California and more announce new key hires

    The latest executive personnel changes from around the industry.

    By Karissa Waddick • July 18, 2022
  • science discovery and technological innovation
    Image attribution tooltip

    NanoStockk/istockphoto.com

    Image attribution tooltip
    Sponsored by OPEN Health

    How digital health is changing the relationship between patients and health providers

    The pandemic has forced the pharmaceutical industry to look at digital in a new way - and it’s driving better health outcomes

    July 18, 2022
  • A black stethoscope rests diagonally on a rainbow flag background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    Janssen extends LGBTQ mental health outreach beyond Pride Month

    The pharma giant’s ‘Depression looks like me’ campaign assembles a ‘one stop shop’ of resources to help combat high rates of severe depression in the LGBTQ community.

    By Karissa Waddick • July 14, 2022